Trial Profile
Randomized Trial Evaluating Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Triamcinolone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms BEVATAAC
- 09 Dec 2016 New trial record